Results 1 to 10 of about 235 (94)
Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion [PDF]
Molecular Cancer, 2017 Kerstin Cornils +2 more
exaly +2 more sources
A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance [PDF]
PLoS ONE, 2016 Laurie L Parker
exaly +2 more sources
Di-san junyi daxue xuebao, 2021 Objective To investigate the laboratory and clinical characteristics of acute lymphoblastic leukemia (ALL) with e1a3 BCR-ABL fusion protein. Methods The clinical data, and results of bone marrow cytology, flow cytometry, karyotyping, fluorescence in situ
CHEN Siyu +6 more
doaj +1 more source
DETECTION OF BCR-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA PATIENTS USING IMMUNOCYTOCHEMISTRY
The Iraqi Journal of Medical Sciences, 2016 Background: Chronic Myeloid leukemia (CML) is a myeloproliferetive disorder associated with chromosomal abnormality, Philadelphia chromosome (Ph), in more than 95% of CML patients. The resulting BCR-ABL fused gene is markers for this type of leukemia. In
Maysaa Abdul Razaq Dhahi +2 more
doaj +6 more sources
Cell Communication and Signaling, 2021 Background The fusion oncoprotein Bcr-Abl is mostly located in the cytoplasm, which causes chronic myeloid leukemia (CML). After moving into the nucleus, the fusion protein can induce apoptosis of CML cells.
Yuhang Peng +5 more
doaj +1 more source
PLoS ONE, 2012 The development of multidrug resistance (MDR) limits the efficacy of continuous chemotherapeutic treatment in chronic myelogenous leukemia (CML). Low molecular weight protein tyrosine phosphatase (LMW-PTP) is up-regulated in several cancers and has been ...
Paula A Ferreira +8 more
doaj +1 more source
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
Advances in Hematology, 2015 BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL ...
Alessandro Morotti +6 more
doaj +1 more source
Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate.
PLoS ONE, 2013 Selective inhibition of BCR/ABL expression by RNA interference has been demonstrated as an effective strategy in CML treatment and a reversal to imatinib resistance.
Yajuan Li +9 more
doaj +1 more source
Apoptosis resistance in chronic myelogenous leukemia [PDF]
Einstein (São Paulo), 2005 The chronic myeloid leukemia (CML) is the three-phasemyeloproliferative disorder, dependent on the expression of theoncoprotein Bcr-Abl, which is the product of the reciprocaltranslocation between chromosomes 9 and 22, resulting in thePhiladelphia ...
Fabíola Attié de Castro +4 more
doaj
Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells. [PDF]
Asian Pac J Cancer Prev, 2021 Al-Rawashde FA +5 more
europepmc +1 more source